OPKO Health swings to Q3 net loss of $53.5 million; Q3 revenue rises 16% to $65.4 million

By Public Technologies
  • OPKO Health swung to a third-quarter 2026 net loss of $53.5 million from net income of $21.6 million a year earlier.
  • Continuing operations revenue rose 16% to $65.4 million, primarily due to higher Lilly royalties, increased Rayaldee sales and international growth.
  • Agreed to sell substantially all remaining BioReference operations to Labcorp for $722 million at closing and up to $150 million additionally.
  • Projected continuing operations revenue of $62 million to $72 million for the three months ending December 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041623PRIMZONEFULLFEED9870587) on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk